Search Results

You are looking at 191 - 200 of 467 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

J. Sybil Biermann

extremity: a review of 349 cases from a single institution . Cancer Treat Rev 2010 ; 36 : 1 – 7 . 2. Becker WT Dohle J Bernd L . Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy . J

Full access

Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy

: Lessons From Medicare Part D,” in this issue of JNCCN (page 1509 ) adds to the current literature on cancer care disparities in that it reveals how state-level variability in Medicare Part D benefits influence adjuvant therapy prescriptions

Full access

Michael B. Streiff

adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group . J Clin Oncol 1996 ; 14 : 2731 – 2737 . 13. Holm T Singnomklao T Rutqvist LE Cedermark B . Adjuvant

Full access

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

method of operation. However, this information is important to review postoperatively because it may better identify patients with aggressive pathologic features potentially suitable for adjuvant therapy clinical trials. The Role of Lymphadenectomy

Full access

Christopher G. Willett

. Locoregional Rectal Cancer: What's New “The rectal cancer guidelines have been completely reworked to include the idea of mirroring the adjuvant therapies that we use in colon cancer,” said Dr. Grothey. “In the past few years, every time our committee looked

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang

2002 ; 9 : 277 – 283 . 22 Motzer RJ Sheinfeld J Mazumdar M . Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ-cell tumors . Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research

Full access

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Thus, in these high-risk patients, offering SLNB would seem reasonable to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. The significance of tumor regression is debatable, with more recent

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

primary surgery, with adjuvant therapy as indicated. For patients not suitable to receive primary surgery, primary treatment recommendations include systemic therapy and/or pelvic radiation therapy (RT) with or without brachytherapy. Systemic therapy is an

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

patients—a Dutch colorectal cancer group study . J Clin Oncol 2005 ; 23 : 6199 – 6206 . 94 Tepper JE O’Connell M Niedzwiecki D . Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114 . J

Full access

Eric Jonasch

is partial or radical nephrectomy or, in select patients, active surveillance. Further treatment is typically not recommended. “Following nephrectomy, adjuvant therapy for RCC has been an exercise in frustration,” he pointed out. Recent studies